This guide equips early-stage, BD, and pre-launch market access teams with the foundations of analogue analysis, its benefits, approaches, and how to overcome common challenges. It also explains how AI can help streamline analogue analysis and deliver better results.
This guide equips HEOR, value and access leaders with the four pillars of modern evidence management: a living evidence library, intelligent curation, dynamic updating of the evidence package, and proactive evidence gap identification. It includes real-world examples of time and cost savings, and a quick self-assessment to see where your team stands.
Sponsored
Two teams can size the same market using the exact same healthcare claims data and land millions of patients apart. The data is identical, but the cohort definition is not, and almost nobody checks the range. While real-world data can map treatment flows, disease progression, outcomes, and cost of care across payers, every insight rests on a definition that usually goes untested and may not even be published at all. In this episode, Scott L. DuVall, PhD, SVP of Real-World Evidence at PurpleLab, whose CARES initiative puts high-precision data and methods behind real-world research, explains which definitional choices move a result, what to ask before building on numbers you didn't produce, and the four requirements he would insist on for every study.
This article examines the growing importance of certifications as a defining standard in pharmaceutical logistics. As regulatory scrutiny intensifies and supply chains become more complex, certifications signal a provider’s ability to meet stringent quality, compliance, and handling requirements. From GDP compliance and specialized training to validated processes and audit readiness, explore how certified logistics partners go beyond basic visibility tools to deliver trust, accountability, and risk mitigation. The piece also highlights how shippers can evaluate partners based on credentials that ensure consistent performance and safeguard sensitive pharmaceutical products throughout the supply chain.
Emerging biopharma companies preparing for a first rare disease launch must balance speed, capital constraints and regulatory uncertainty while building the capabilities required for commercial success. This POV examines five critical launch success factors, including pre-launch preparation, governance, integrated infrastructure, organizational alignment and coordinated execution. Through a real-world launch example, readers will learn how an integrated partnership model can accelerate readiness, reduce operational complexity, preserve strategic control and support patient access from day one.
Launching and commercializing complex therapies requires agility, specialized expertise and the ability to adapt as market conditions evolve. This POV explores how an integrated commercialization model can give biopharma teams flexible access to end-to-end or select capabilities while helping reduce cost, complexity and overall risk. Through real-world case studies, readers will learn how scalable infrastructure, experienced commercial leadership and data-driven execution can support successful launches, global expansion and continued value creation across the product life cycle.
First-time biopharma launchers face interconnected challenges, including limited capital, lengthy preparation timelines, regulatory uncertainty and greater pressure to meet commercial forecasts. This white paper examines why traditional launch approaches often fall short and outlines practical strategies for building the right capabilities at the right time. Readers will learn how earlier planning, integrated execution and a flexible partnership model can help reduce launch risk, improve capital and time efficiency, and position a product to achieve its full commercial potential. [Transforma...WP_TL_0226 | PDF]
Emerging biotech companies often face a critical commercialization decision: out-license an asset to gain immediate resources or retain ownership and pursue greater long-term value. This white paper explores the financial, operational and strategic implications of that decision, examining how commercialization models, capital constraints, launch readiness and risk management can influence enterprise value. Readers will gain practical insights to help evaluate commercialization pathways, preserve optionality and position assets for sustainable growth in today's increasingly complex market.
High-value freight is moving through a more complex risk environment. This whitepaper explores how tighter capacity, rising cargo theft severity, freight fraud, and greater liability scrutiny are reshaping transportation strategy. It also outlines a modern approach to carrier assessment, risk-based controls, and balancing capacity with accountability for shippers of critical, high-consequence freight.
How Human-Led, AI-Powered systems designed specifically for healthcare turn data overload into decision-ready insight. Healthcare marketers are flooded with data, from patient conversations and HCP feedback to social listening, CRM activity, and market signals, yet actionable insights remain difficult to uncover. This eBook explores why generic AI often falls short in healthcare and shows how a Human-Led, AI-Powered approach can turn complex data into trusted, decision-ready intelligence.
How to efficiently and accurately plan for and comply with aggregate spend, drug price transparency laws, and government price reporting requirements.
Omnichannel is no longer enough. Learn how omnideployment integrates AI, content, digital marketing, and field engagement into a single accountable system that drives smarter launches, stronger HCP engagement, and measurable commercial performance.
Being AI-enabled is no longer enough. Learn how AI-native commercialization partners can help pharmaceutical companies orchestrate intelligence across markets, navigate Europe’s complex healthcare landscape, and create greater value through expertise, technology, and outcomes-based collaboration.
Scientific storytelling is becoming a critical differentiator in Medical Affairs. Discover how leading organizations are moving beyond standalone assets and data-heavy communications to create connected scientific narratives, activate modern influence networks, and deliver more meaningful engagement with healthcare professionals.
The future of commercialization extends beyond product promotion and patient acquisition. Learn how Direct-to-Disease models enable pharmaceutical companies to build trusted, digitally enabled ecosystems that improve access, adherence, and long-term outcomes.
EHR media can look similar on a media plan while differing significantly in data sources, placements, targeting, reporting and access to the clinical environment. This whitepaper gives life sciences marketers a practical framework for evaluating EHR media beyond headline reach. Learn the questions to ask about where messages appear, how target HCPs are reached, what drives message delivery, how campaign performance is measured and how transparency can be independently validated. It also explores how first-party EHR data, clinical context and verified standards can support more relevant, measurable point-of-care media strategies.
Affordability can be the difference between a prescription written and a prescription filled. This case study examines how one brand's automated pharmacy affordability program helped reduce patient cost barriers and what happened when that support was temporarily removed, resulting in higher abandonment rates and fewer filled prescriptions.
This infographic leverages IQVIA data and analytics to explore how one pharmaceutical brand used CoverMyMeds’ prior authorization strategies to achieve an observed average 22 percentage point improvement in claim approval rates—growing and defending market share in a highly managed class.
A cross-disciplinary panel expand on how pharma leaders navigate pricing uncertainty, shifting policy, and reputation risk.
You've seen it before: an AI pilot that works in testing, then stalls the moment someone asks you to reproduce the result. The cause usually isn't the model—it's what wasn't built around it. Komodo Health built this framework from its deployments at Genmab and Ipsen, identifying three components that separate AI that scales from AI that stalls: reproducible methods, modular workflows, and governance built to keep pace with regulation. FDA guidance is tightening. EU AI Act enforcement is approaching. Build this infrastructure now, and you can prove compliance the moment someone asks. Wait, and you'll retrofit it under pressure. Download the framework from the company that builds this infrastructure, not the one writing about it from the sidelines.
This eBook highlights Werner’s premium and expedited shipping solutions designed specifically to address the high-stakes requirements of the $1.6 trillion global pharmaceutical industry. It details how their specialized multimodal services—including 24/7 dedicated operational teams and experienced driver networks—mitigate risks for high-value, perishable and time-sensitive medical freight.
In this article, we explore how cold-chain logistics are evolving to support the unique demands of the pharmaceutical industry. From precision temperature control and proactive compliance management to real-time visibility and mission-critical support systems, discover the strategies that help ensure safe, reliable delivery of temperature-sensitive medicines. Featuring insights into emerging expectations for traceability, rapid response protocols, and customized logistics solutions, this piece highlights how best-in-class cold-chain practices build resilience and protect product integrity.
How pharmaceutical and life sciences fleets can uncover hidden operational costs by connecting maintenance, telematics, fuel, routing, and lifecycle decisions
DSCSA compliance did not end with implementation. Learn what your organization should monitor, test and strengthen now that FDA enforcement is underway.
Is your serialization system ready to grow with your business? Explore a practical roadmap for improving scalability, integration, aggregation and partner connectivity.
Breaking cases or building mixed pallets? Learn why aggregation is essential for maintaining serialized product relationships without adding costly scans, errors and operational delays.
“GS1-aligned” does not always mean independently validated. Learn how GS1 standards certification can reduce EPCIS data risk and strengthen trading partner interoperability.
Is your organization operationally ready for DSCSA enforcement? Use this checklist to identify potential gaps across serialization, aggregation, EPCIS exchange, exception management and audit readiness.
See how STEPLogic Trace helps pharmaceutical supply chains produce certified EPCIS outputs, manage serialization and aggregation, and exchange data more confidently with trading partners.
As AI transforms how biopharma operates, the gap between companies with connected, structured data and those without is only widening. Courier Health Founder and CEO, Danny Sigurdson, unpacks what it takes to harness AI and the role it plays in orchestrating more seamless patient experiences.